Supporting NCI

  • 12:25

Immunicum AB (publ) today announced that the Company will deliver a genetically modified adenovirus vector to the American Frederick National Laboratory for Cancer Research (FNLCR), that on behalf of the National Cancer Institute (NCI), conducts research on new drugs for cancer and AIDS.

Comments are closed.